Arcellx Inc’s Anito-cel: Promising Efficacy and Best-in-Class Safety Profile Justify Buy Rating
Analyst John Newman from Canaccord Genuity maintained a Buy rating on Arcellx Inc (ACLX – Research Report) and keeping the price target ...
Promising Trial Results and Pipeline Expansion Justify Buy Rating for Iovance Biotherapeutics
Yanan Zhu, an analyst from Wells Fargo, maintained the Buy rating on Iovance Biotherapeutics (IOVA – Research Report). The associated ...